We have previously reported that neutrophil elastase (NE) downregulates transforming growth factor-(TGF-) maintained tropoelastin mRNA levels in lung fibroblasts through transactivation of the epidermal growth factor receptor (EGFR)/Mek/Erk pathway, which is dependent on the NE-initiated release of soluble EGFR ligands. In the present study, we investigated the mechanism by which epidermal growth factor (EGF) downregulates tropoelastin expression. We found that EGF downregulates tropoelastin expression through inhibiton of TGFsignaling. We show that EGF does not prevent the TGF--induced nuclear accumulation of Smad2/3; rather, EGF stabilizes the short-lived Smad transcriptional corepressor TG-interacting factor (TGIF) via EGFR/Mek/Erk-mediated phosphorylation of TGIF. Elevated TGIF levels, either by overexpressing TGIF or by preventing its degradation, are sufficient to inhibit TGF--induced tropoelastin expression. Moreover, TGIF is essential for EGF to downregulate tropoelastin expression as siRNA knockdown of TGIF blocked EGF-induced downregulation of tropoelastin. Finally, we demonstrated that NE treatment, which releases EGF-like growth factors, causes stabilization of TGIF through the EGFR/Mek/Erk pathway. These results suggest that EGFR/Mek/Erk signaling specifically antagonizes the proelastogenic action of TGF-in lung fibroblasts by stabilizing the Smad transcriptional corepressor TGIF.
It has been well documented that TGF-upregulates tropoelastin expression through increasing tropoelastin mRNA stability (15, 18, 24). TGF-has been shown to stabilize tropoelastin mRNA in a Smad-dependent manner (19). Lungs of Smad3 null mice exhibit downregulated levels of tropoelastin mRNA from the end of alveolarization through adulthood and decrease in interstitial elastin deposition, and develop destructive emphysematous changes (7). We recently demonstrated that tropoelastin expression in RFL-6 fibroblasts is primarily maintained by autocrine TGF-(10), so it is plausible that deficient endogenous TGFsignaling could contribute to the insufficient resynthesis/repair of elastin in the emphysematous lung.
We have demonstrated that NE downregulates tropoelastin mRNA levels in lung fibroblasts through the EGFR/Mek/Erk pathway (10). EGF-like growth factors, released by elastase, are required for the downregulation of tropoelastin expression (9, 10, 21). EGF has been shown to downregulate tropoelastin expression through the EGFR/Mek/Erk pathway (9, 21). We recently demonstrated that NE and EGF downregulate tropoelastin expression by decreasing tropoelastin mRNA stability (10). However, the mechanism by which EGF suppresses tropoelastin expression remains largely unknown. Since endogenous TGF-has been shown to be responsible for tropoelastin expression in RFL-6 fibroblasts and EGF has been shown to inhibit TGF-signaling, we hypothesize that EGF suppresses tropoelastin expression through inhibition of endogenous TGF-signaling.
In the present study we probed the molecular mechanism by which NE downregulates tropoelastin expression. Since NE downregulates tropoelastin expression in lung fibroblasts in an EGFR ligand-dependent manner, we use EGF to investigate the pathway. We demonstrate that EGF, by activating EGFR/Mek/Erk pathway, suppresses tropoelastin expression through
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Preparation of nuclear extract and cytosolic fraction--After treatment, cell cultures were quickly washed twice with PBS at room temperature. All of following steps were performed at 4°C as follows. One ml of ice-cold hypotonic lysis buffer (20 mM Hepes-Na, pH 7.6, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 10 mM NaF, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 1 mM PMSF and 0.5 mM DFP) was added per well of 6-well cluster plate. Cells were allowed to swell on ice for 20 minutes before they were scraped and collected. Nuclei and associated cytoskeleton were pelleted by centrifugation at 600xg for 10 min in a table-top centrifuge. The supernatant (cytosolic fraction) was transferred to a new tube. The pellet was resuspended in 50 µl of nuclear extraction buffer (hypotonic lysis buffer plus 500 mM NaCl). After incubation and rocking for 30 min, the nuclear extracts were cleared of debris by centrifuge and kept at -80°C.
Western blot analysis--Equal amounts of samples were mixed with appropriate volume of 3x
SDS-PAGE sample buffer with 2-mercaptoethanol and heated for 10 min at 100°C, and all of the samples were loaded on 4% stacking and 9% separating SDS-PAGE minigels. After electrophoresis, the proteins were electroblotted onto a 0.45-µm pore size nitrocellulose membrane (Schleicher and Schuell). Transferred proteins were stained briefly with 0.1% (wt/vol) Ponceau S in 5% acetic acid (Sigma) to check for even loading and transfer. Membranes were blocked in 5% (wt/vol) nonfat milk powder in TBST (TBS (10 mM Tris·HCl, pH 7.4, 150 mM NaCl) and 0.05% Tween 20) for 1 h, washed three times for 10 min with TBST, incubated for 1 h with primary antibodies diluted in TBST, and then washed three times for 10 min with TBST and incubated for 1 h with peroxidase-conjugated secondary IgG diluted in TBST. The membranes were washed twice for 10 min with TBST and once for 5 min with TBS, and Page 8 of 41 immunodetection of proteins was performed with enhanced chemiluminescence by using LumiGlo chemiluminescence detection kit (Kirkegaard and Perry Laboratories).
Northern blot analysis--Total RNA was extracted from cell cultures by using TRIzol reagent (Invitrogen). Equal amount of total RNA (7 µg/lane) were electrophoresed through 1.0% agarose-formaldehyde gels, capillary transferred to nylon membranes (Osmonics, Minnetonka, MN), and cross-linked to filters by ultraviolet irradiation (Stratalinker; Stratagene). To compare integrity and correct RNA loading, blots were stained with 0.04% methylene blue in 0.5 M sodium acetate. Membranes were prehybridized at 42°C for 2 h in a solution containing 50% formamide, 5x sodium chloride and sodium citrate (SSC: 1x SSC is 0.15 M NaCl and 0.015 M sodium citrate, pH 7.0), 5x Denhardt's reagent, 0.5% sodium dodecyl sulfate (SDS), and 100 µg/ml denatured salmon sperm DNA and were hybridized overnight in a solution containing 50% formamide, 5x SSC, 10% dextran sulfate, 0.5% SDS, and 32P-labeled cDNA fragments of desired genes. After hybridization, membranes were washed (2 times in 1x SSC and 0.1% SDS at 55°C for 1 h) and exposed at -80°C in a cassette with double intensifying screens to X-ray film (Abgene). The bands were quantified by densitometry within the linear range.
Cell culture and transient transfection of cells--RFL-6 fibroblasts were seeded in complete growth medium supplemented with 10% FBS into 12-well cluster plates (100,000 cells/well).
Cells at ~90% confluence on the day after seeding were placed in 1 ml of serum-free, antibioticfree medium. Cells were transfected with Lipofectamine-2000 (Invitrogene) by following the manufactures' instructions. After 5 h, transfection medium was aspirated and 2 ml of complete growth medium supplemented with 10% FBS were added per well, and the cells were maintained overnight. After 24 h, medium was replaced with 2 ml of serum-free, antibiotic free medium. After 16 h, cell lysates were harvested.
Immunocytochemistry--The intracellular localization of Smad2/3 was analyzed by indirect immunofluorescence. For this purpose, cells were seeded on glass coverslips placed into 12-well cluster plates at a density of 50,000 cells per well and grown overnight in complete culture medium supplemented with 10% FBS. Cells were replaced with serum-free, antibiotic-free medium on the day after seeding when cells were 50% confluent. After 4 h starvation, cells were treated for 1 h with or with out EGF, TGF-1, or their combination. Cells were quickly rinsed twice with PBS and then fixed with 3.7% paraformaldehyde in PBS for 5 min at room temperature, quickly washed 3 times with large volume of PBS, permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature, quickly rinsed 3 times with large volume of PBS, and blocked overnight at 4°C with blocking solution (3% normal donkey serum and 1% bovine serum albumin in PBS). We also designed another target sequence which is homologous to published shRNA to human TGIF (32):
shRNA 756 (756-774): ATCTGGACCCAGTCCAAAT.
Hairpin sequence UUCAAGAGA was used to construct siRNA expression vectors as described (4) . A double-stranded oligonucleotide encoding a hairpin siRNA was inserted into linearized RNAi-Ready pSIREN-RetroQ vector. The sequences of plasmid were confirmed by automated DNA sequencing in both sense and antisense directions at the DNA-protein core facility at Boston University Medical Center. (Fig. 3A) . TGIF is recognized as double protein bands, with the higher and lower mobility bands corresponding to nonphospho-and phospho-TGIF, respectively (22). The phosphorylated form is more abundant. EGF stimulation led to a rapid increase in the relative amount of phosphorylated TGIF at 15 min. Phosphorylated TGIF levels remained elevated at 30 min and 2 h of treatment and total TGIF levels were increased at these time points.
We examined what pathway downstream of EGF signaling is involved in the EGFmediated stabilization of TGIF. Since EGF prevents TGF--induced tropoelastin expression through the EGFR/Mek/Erk pathway, we anticipated that EGF might stabilize TGIF through the same pathway. Indeed, AG1478 or U0126 treatment prevented the EGF-mediated increase in phosphorylated and total TGIF levels (Fig 3B) , demonstrating that the EGFR/Mek/Erk pathway is required for this action.
Elevated TGIF levels are sufficient to downregulate tropoelastin expression--If EGF
downregulates tropoelastin expression through stabilization of TGIF, tropoelastin expression should be downregulated when the TGIF levels are increased either by preventing its degradation or by overexpression of TGIF. To prevent TGIF degradation, cells were treated for 2 h with or without the proteasome inhibitor lactacystin. Nuclear extracts were prepared and TGIF levels were analyzed by Western blot. Lactacystin caused a dramatic increase in TGIF levels (Fig. 4A ).
Thus TGF--mediated tropoelastin expression was investigated under these conditions. Cells were treated for 1 h with or without lactacystin and then stimulated for an additional 24 h with or without TGF-1. Treatment of cells with lactacystin dramatically reduced tropoelastin protein and mRNA levels (Fig 4B and 4C) . Moreover, TGF-1 treatment did not induce tropoelastin expression in the presence of lactacystin, suggesting that lactacystin interfered with the TGF-1-mediated tropoelastin expression. Thus, lactacystin, similar to EGF, leads to increased TGIF levels and decreased tropoelastin expression and prevents TGF--induced tropoelastin expression in RFL-6 fibroblasts.
In order to further explore the role of TGIF in EGF-mediated inhibition of tropoelastin expression, we also analyzed tropoelastin expression in cells that overexpress human TGIF wild type (hTGIF WT) or hTGIF mutant (hTGIF 1-148:177-262), which is devoid of the Smad interaction domain and is not able to interact with Smad2/3 (35). As shown in Fig. 4D , tropoelastin expression was inhibited by overexpression of hTGIF WT in a dose-dependent manner, but was not affected by overexpression of hTGIF 1-148:177-262, suggesting that the interaction between TGIF and Smad is required for TGIF to downregulate tropoelastin expression.
The inhibitory effect of TGIF on TGF-induced tropoelastin expression was also confirmed by overexpression of TGIF. As shown in Fig. 4E , the TGF-1-mediated uooregulation of tropoelastin expression was inhibited by overexpression of hTGIF.
Taken together, these results suggest that elevated TGIF levels are sufficient to suppress tropoelastin expression in RFL-6 fibroblasts.
Elevated TGIF levels are essential for EGF to downregulate tropoelastin expression--
To further confirm the role of TGIF in EGF downregulation of tropoelastin expression, we generated RFL-6 cell lines with reduced levels of TGIF. To knock down TGIF, we constructed three pSIREN-RetroQ retrovial vectors that target three different regions in rat TGIF mRNA.
RFL-6 fibroblasts were infected with retroviruses encoding TGIF siRNA and stable transfectants were achieved after selection with puromycin. The TGIF levels in stable transfectants were analyzed by Western blot (Fig. 5A) . TGIF levels were knocked down by approximately 80% in shRNA226-and shRNA486-RFL-6 cells, in comparison with RetroQ-and shRNA756-RFL-6 cells.
The inhibitory effect of EGF on tropoelastin expression was then analyzed in cells with reduced levels of TGIF. As shown in Fig. 5B , tropoelastin protein levels were downregulated by EGF in a dose-dependent manner in RetroQ-and shRNA756-RFL-6 cells that have normal TGIF levels and responded to EGF treatment with an increase in TGIF levels. However, the inhibitory effect of EGF on tropoelastin protein was dramatically diminished in shRNA226-and shRNA486-RFL-6 cells whose TGIF levels are knocked down by RNAi. Similar results were observed in TGF-treated cells (data not shown). To investigate whether EGF signaling was functioning properly in those cells, EGFR levels were also probed. EGFR levels were similar and were downregulated by EGF in a dose-dependent manner in all four RFL-6 cell lines, suggesting that the reduced ability of EGF to downregulate tropoelastin in the TGIF knocked-down cells was not the result of altered EGFR signaling. These data indicate that TGIF is required for EGFmediated inhibition of tropoelastin expression.
NE-initiated EGFR/Mek/Erk signaling leads to stabilization of TGIF--NE
downregulates tropoelastin mRNA levels through transactivation of the EGFR/Mek/Erk pathway, dependent on the release of EGF-like growth factors (9, 10, 21). Since EGF acts via TGIF, we examined whether NE treatment results in stabilization of TGIF. To address this question, cells were treated for 1 h with or without AG1478 or U0126 and then treated for an additional 1 h with or without EGF or NE and TGIF levels were measured. Similar to EGF, NE led to phosphorylation and stabilization of TGIF, which coincided with Erk activation (Fig. 6) .
TGIF phosphorylation and stabilization were prevented by incubation with AG1478 and U0126, suggesting that NE stabilizes TGIF via the EGFR/Mek/Erk pathway. Importantly, NE treatment does not result in direct inactivation of endogenous TGF-; instead, NE treatment stimulated the release of active TGF-from RFL-6 cells indicating that the ability to interfere with TGF-signaling through EGFR/Mek/Erk-mediated TGIF stabilization is the basis of NEdownregulation of tropoelastin mRNA.
Discussion
We have demonstrated previously that treatment of neonatal rat lung fibroblasts and RFL-6 fibroblasts with NE downregulates tropoelastin mRNA levels through the release of EGFlike growth factors and activation of the EGFR/Mek/Erk pathway (9, 10). In the present study, we examined the mechanism by which EGF downregulates tropoelastin expression in RFL-6 cells. In this system, tropoelastin is maintained by endogenous TGF-and can be induced by exogenous TGF-. Our data indicate that EGF downregulates tropoelastin expression by abrogation of TGF-signaling. In this regard, we observed that EGF treatment leads to the stabilization of the Smad corepressor TGIF, indicating a mechanism whereby EGF interferes with TGF--mediated tropoelastin expression. These results suggest a potentially important process whereby EGF-like ligands and TGF-act to control tropoelastin in the lung.
EGF has been shown to downregulate tropoelastin expression (9, 10) and to prevent TGF--induced tropoelastin expression (present study) through the EGFR/Mek/Erk pathway.
Consistently, we demonstrate here that EGF stabilizes TGIF through the EGFR/Mek/Erk pathway, suggesting that EGF might downregulate tropoelastin expression through stabilization of TGIF. In this study we also demonstrate that elevated levels of TGIF, either by preventing its degradation or by overexpression of TGIF, are sufficient to downregulate tropoelastin expression. Moreover, shRNA knockdown of TGIF made cells refractory to EGF-mediated downregulation of tropoelastin. These loss-of-function and gain-of-function experiments, together with AG1478 and U0126 inhibitor assays, establish that EGF inhibits TGF--induced tropoelastin expression through the EGFR/Mek/Erk-mediated stabilization of Smad corepressor TGIF.
TGIF could inhibit TGF-signaling through a variety of mechanisms. It has been shown that the interaction between Smad2 and TGIF can be stabilized by c-Jun, which is a downstream effector of the c-Jun N-terminal kinase (JNK) pathway (28). This mechanism is probably not involved in the RFL-6 cells as the JNK specific inhibitor, SP600125, did not affect EGF downregulation of tropoelastin expression in these cells 2 . TGIF has also been implicated in the degradation of Smad2 (32). However, we did not observe any changes in total Smad2 levels with EGF treatment (Fig 3A) , suggesting that Smad2 degradation is not likely the major mechanism involved. TGIF has also been suggested to inhibit TGF-signaling by sequestering the cytoplasmic promyelocytic leukemia protein (cPML) in the nucleus (31), thus preventing its association with Smad anchor for receptor activation (SARA) in the cytoplasm, which is required for the activation and nuclear translocation of Smad2/3 (20). This mechanism also does not fit the data from our system because the TGF--induced nuclear translocation of Smad2/3 was not affected by EGF in RFL-6 fibroblasts (Fig. 2) . TGIF is also suggested to inhibit TGF-signaling through recruitment of HDACs (35), but treatment of RFL-6 cells with the HDAC inhibitor trichostatin A neither prevented EGF-mediated downregulation of tropoelastin expression nor enchanced the TGF-induced tropoelastin expression 2 . TGIF is also suggested to inhibit TGFsignaling through the replacement of coactivators, such as CBP/p300, from the Smad transcription complex (35), thus, additional studies will be required to carefully evaluate this possibility in the RFL-6 cell system.
Since tropoelastin expression is primarily maintained by TGF-, other negative modulators of tropoelastin expression might work through inhibition of TGF-signaling.
Phorbol ester has been shown to downregulate tropoelastin expression (14, 27), but the mechanism is unknown. Phorbol ester is known to transactivate EGFR signaling in an ADAM (a disintegrin and metalloproteinase)-dependent manner (2), so it is possible that phorbol ester inhibits tropoelastin expression through stabilization of TGIF. bFGF (basic fibroblast growth factor) has been shown to downregulate tropoelastin expression (3, 8, 29) in an Erk-dependent manner (6) and to antagonize TGF--induced tropoelastin expression (8). So, it is also possible that bFGF might also inhibit tropoelastin expression through Erk-mediated stabilization of TGIF.
Thus, the ability to stabilize TGIF through Erk-dependent phosphorylation might be a consistent feature of tropoelastin downregulation mechanisms.
Pulmonary emphysema is associated with unlimited elastolysis and insufficient repair of Based on these previous findings and our present results, we suggest a model by which EGF suppresses TGF--induced tropoelastin expression (Fig. 7) . Tropoelastin protein levels correlate with tropoelastin mRNA levels, which are primarily determined by the turn-over rate of the message in the mature lung. Our data suggest that a, yet unspecified, TGF--inducible cytosolic factor X potentially functions to stabilize tropoelastin mRNA. Smad corepressor TGIF levels are normally very low due to a high turn-over rate, such that TGF-signaling can lead to transcriptional transactivation of factor X, which in turn stabilizes tropoelastin mRNA, for instance, by binding to the GA-rich sequence in the 3'-UTR and/or interfering with the binding of a destabilizing factor(s) to exon 30 of tropoelastin mRNA. Both mechanistic scenarios would 22 lead to upregulation of tropoelastin expression. EGF signaling could interfere with this process by repressing the expression or activity of factor X by stabilizing the Smad corepressor TGIF, resulting in destabilization of tropoelastin mRNA and decreased tropoelastin expression. It will be important to continue to evaluate the interactions of the EGF and TGF-signaling pathways with respect to the regulation of tropoelastin expression to gain a more complete appreciation of how elastin production is controlled in vivo normally, after injury, and in disease states. The results shown are representative of experiments that were repeated 3 times. The results shown are representative of experiments that were repeated at least 3 times. Postconfluent serum-starved cells were first treated for 1 h with or without 10 µM AG1478 or 25 µM U0126 and then treated for an additional 1 h with or without 10ng/ml EGF or 5 µg/ml NE.
Nuclear extracts were prepared. Thirty µg of total protein from each sample were analyzed by
Western blot with antibodies against TGIF or phospho-Erk. Ponceau S staining is provided as loading control. The results shown are representative of an experiment that was repeated 3 times. 
